Addition of Daratumumab to Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed MM

June 2-6, 2017; Chicago, Illinois
Daratumumab addition to standard therapy was associated with an ORR of 100% after median follow-up of 10.8 months.
Format: Microsoft PowerPoint (.ppt)
File Size: 530 KB
Released: June 6, 2017

Acknowledgements

Supported by educational grants by
AbbVie
Amgen
AstraZeneca
Celgene Corporation
Genentech
Halozyme Therapeutics
Incyte
Merck & Co., Inc.

Related Content

From Clinical Care Options (CCO), a video webinar on fundamentals of CAR T-cell therapy for pharmacy and managed care professionals

Craig Freyer, PharmD Zahra Mahmoudjafari, PharmD, BCOP, DPLA Pharmacists: 0.25 contact hours (0.025 CEUs) Released: September 24, 2021 Expired: September 23, 2022

Clinical Care Options (CCO) commentary in which Dr. Daniel Pollyea provides his strategies for treating patients with myelodysplastic syndrome (MDS)

Daniel Pollyea, MD, MS Released: September 24, 2021

Global perspective of key studies presented at ASCO, EHA, ICML 2021 from an international expert in CLL from Clinical Care Options (CCO)

George Follows, BM, BCh, PhD Released: September 17, 2021

Analysis of key studies in hematologic malignancies from ASCO 2021 presented by Drs. Ian Flinn, Shaji Kumar, and Eunice Wang, as reported by Clinical Care Options (CCO)

Ian W. Flinn, MD, PhD Shaji K. Kumar, MD Eunice S. Wang, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: September 13, 2021 Expired: September 12, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue